History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications

Abstract

Intraperitoneal (IP) delivery of cisplatin was developed in the 1970s based on a strong pharmacologic rationale and rodent models. Its advantage over intravenous (IV) administration was supported initially by observational studies in treating recurrent ovarian cancer and eventually by better outcomes from IP vs. IV cisplatin in randomized studies in patients undergoing optimal surgical debulking at diagnosis. In the past two decades, with the introduction of novel anticancer interventions (such as taxanes, bevacizumab, inhibitors of DNA repair, and immune check point inhibitors), advantages of IP drug delivery are less clear and concerns are raised on cisplatin's therapeutic index. The discovery of BRCA genes and their key role in DNA repair, on the other hand, have strengthened the rationale for IP drug delivery: high grade serous cancers arising in the Mullerian epithelium in association with hereditary or somatic BRCA function inactivation are linked to peritoneal spread of cells that - while initially sensitive - are prone to emergence of platinum resistance. Therefore, selection of patients based on genomic features and focusing on the better tolerated IP carboplatin are ongoing. Recent examples of leveraging the peritoneal route include (1) targeting the cell membrane copper transport receptor - that is shared by platinums - by the combination of the proteasome inhibitor bortezomib and IP carboplatin; and (2) enhancing IP 5-fluoro-2-deoxyuridine cytotoxicity when coupled with PARP inhibition.

Keywords

Platinum drugs / intraperitoneal administration / epithelial ovarian carcinoma

References

[1] Muggia FM,Hoeschele JD,Howell SB.Platinum antitumor complexes: 50 years since Barnett Rosenberg’s discovery..J Clin Oncol2015;33:4219-26

[2] Markman M,Hakes T.Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin..J Clin Oncol1991;9:389-93

[3] Seltzer V,Kaplan B.Recurrent ovarian carcinoma. Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent..Gynecol Oncol1985;21:167-76

[4] Markman M,Webster K.Duration of response to second-line platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design..J Clin Oncol2004;22:3120-25

[5] Miki Y,Shattuck-Eidens D.A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1..Science1994;266:66-71

[6] Wooster R,Lancaster J.Identification of the breast cancer susceptibility gene BRCA2..Nature1995;378:789-92

[7] Snouwaert JN,Latour AM.BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a BRCA1 transgene..Oncogene1999;18:7900-7

[8] Moynahan ME,Jasin M.BRCA2 is required for homology-directed repair of chromosomal breaks..Mol Cell2001;7:263-72

[9] The Cancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinoma..Nature2011;474:609-15 PMCID:PMC3163504

[10] Armstrong DK.Role of intraperitoneal therapy in the initial mangement of ovarian cancer..J Clin Oncol2019;37:2416-19

[11] Vergote I,Chiva L.Is there a role for intraperitoneal chemotherapy, including HIPEC, in the management of ovarian cancer?.J Clin Oncol2019;37:2420-23

[12] Brodovsky HS,Horton J.Comparison of melphalan with cyclophosphamide, methotrexate and 5-fluorouracil in patients with ovarian cancer..Cancer1984;53:844-52

[13] Beck RE.Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide..Can Med Assoc J1968;98:539-41 PMCID:PMC1923922

[14] Hasan J.Oral melphalan as a treatment for platinum-resistant ovarian cancer..Br J Cancer2003;88:1828-30 PMCID:PMC2741128

[15] Young RC,Hubbard SP.Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy..N Engl J Med1978;299:1261-66

[16] Young RC,Nieberg RE.Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or cyclophosphamide cisplatin-a gynecologic oncology group study..J Clin Oncol2003;21:4350-55

[17] Muggia FM,Bono VH.Cis-dichlorodiammineplatinum (II): the trail from an inert electrode to a therapeutic solution. Introduction to Proceedings of NCI Conference on cis-platinum and testicular cancer..Cancer Treat Rep1979;63:1431

[18] Dedrick RL,Bungay PM.Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer..Cancer Treat Rep1978;62:1-11

[19] Jones RB,Myers CB.High volume intraperitoneal chemotherapy with methotrexate in patients with cancer..Cancer Res1981;41:55-9

[20] Speyer JL,Collins JM,Klecker RW Jr.Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans..Cancer Res1981;41:1916-22

[21] Ozols RF,Speyer JL.Phase I and pharmacological study of Adriamycin administered intraperitoneally in patients with ovarian cancer..Cancer Res1982;42:4265-9

[22] Dedrick RL.Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure..J Natl Cancer Inst1996;89:480-7

[23] Howell SB,Markman M.Long term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy..J Clin Oncol1987;5:1607-12

[24] Alberts DS,Hannigan EV.Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer..N Engl J Med1996;335:1950-5

[25] Markman M,Alberts DS.Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group..J Clin Oncol2001;19:1001-7

[26] Armstrong DK,Wenzel L.Intraperitoneal cisplatin and paclitaxel in ovarian cancer..N Engl J Med2006;354:34-43

[27] Gore M,Vergote I.Intraperitoneal chemotherapy in ovarian cancer remains experimental..J Clin Oncol2006;4528-30

[28] Ozols RF,Greer BE.Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study..J Clin Oncol2003;21:3194-200

[29] Walker JL,Wenzel L.Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study..J Clin Oncol2019;37:1380-90 PMCID:PMC6544459

[30] van Driel WJ,Sikorska K.Hyperthermic intraperitoneal chemotherapy in ovarian cancer..N Engl J Med2018;378:230-40

[31] Batista TP.Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?.Cancer Drug Resist2020;3:666-71

[32] Da Costa AA,Baiocchi G.Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer..Ann Surg Oncol.2015;22 Suppl 3:S971-8

[33] Schaaf L,Ulmer C.Hyperthermia synergizes with chemotherapy by inhibiting PARP1-dependent DNA replication arrest..Cancer Res2016;76:2868-75

[34] Provencher DM,Parulekar WR.OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer..Ann Oncol2018;29:431-38 PMCID:PMC6658709

[35] Colgan TJ,Cole DE,Rosen B.Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status..Am J Surg Pathol2001;25:1283-89

[36] Piek JM,Zweemer RP.Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer..J Pathol2001;195:451-6

[37] Labidi-Galy SI,Hallberg D.High grade serous ovarian carcinomas originate in the fallopian tube..Nat Commun2017;8:1093 PMCID:PMC5653668

[38] Tan DSP.Chemotherapy for patients with BRCA1 and BRCA2-mutated ovarian cancer: same or different?.Am Soc Clin Oncol Educ Book2015;35:114-21

[39] Lesnock JL,Tian C.BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study..Br J Cancer2013;108:1231-37 PMCID:PMC3619264

[40] Kwa M,Downey A.Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal chemotherapy..Ann Surg Oncol2014;21:1468-73

[41] Howell SB,Larson CA.Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs..Mol Pharmacol2010;77:887-94 PMCID:PMC3202487

[42] Jandial DD,Larson CA,Wrasidlo WJ.Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1..Clin Cancer Res2009;15:553-60 PMCID:PMC2707998

[43] Jandial DA,Howell SB.A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study..Gynecol Oncol2017;145:236-42 PMCID:PMC5706109

[44] Muggia FM,Muderspach L.Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin)..Gynecol Oncol1997;66:290-94

[45] Muggia FM,Alberts DS.Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy-a randomized phase II study by the Southwest Oncology Group..Gynecol Oncol1996;61:395-402

[46] Geng L,Wagner JM,Karnitz LM.Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil..PLoS One2011;6:e28862 PMCID:PMC3240632

[47] Huehls AM,Huntoon CJ.Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells..Cancer Res2011;71:4944-54 PMCID:PMC3138894

[48] Zylberberg B,Salat-Baroux J,Lipp B.[Polychemotherapy of ovarian cancer via combined intravenous and intraperitoneal routes. Technic and preliminary results]..J Gynecol Obstet Biol Reprod (Paris)1986;15:671-6

[49] Kirmani S,McClay EF.A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer..Gynecologic Oncology1994;54:338-44

[50] Polyzos A,Kosmas C.A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer..Oncology1999;56:291-6

[51] Gadducci A,Chiara S.Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomised trial of the Gruppo Oncologico Nord-Ovest..Gynecol Oncology2000;76:157-62

[52] Yen MS,Lai CR,Ng HT.Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer..Int J Gynaecol Obstet2001;72:55-60

[53] Jaaback K,Lawrie TA.Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer..Cochrane Database Syst Rev2016;1CD005340

[54] The role of intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer..Toronto (ON): Cancer Care Ontario 2012 Jun 25 [Education and Information 2011 Sep]. Program in Evidence-based Care Evidence-based Series No:4-21.